On Sunday, March 3, we hosted a YouTube Live with Jackie Garlich of 20/20 Glance recapping all the FDA approvals in eyecare in 2018!
For those of us with busy schedules who still want to keep up with vital optometry news, 20/20 Glance is the newsletter. Garlich’s quick recaps of crucial updates and releases, along with her humor and great writing, make it enjoyable as well as interesting.
In this video, we discussed all the FDA approvals related to eyecare in 2018. We covered topics ranging from developments in artificial tears to emerging technologies in eyecare, and more!
Here’s a quick recap from 20/20 Glance of the eye-related FDA approvals in 2018:
- Dexycu – It’s a sustained-release one-time injection of dexamethasone in the anterior chamber after cataract surgery.
- Systane Complete – This artificial tear gives relief to patients with evaporative dry eye, aqueous deficient dry eye, and/or a combo of both.
- IDx-DR – An artificial intelligence diagnostic system that analyzes fundus photos to determine if diabetic retinopathy is present.
- Artificial Iris Implant – The first prosthetic iris for adults and children with congenital aniridia or other iris defects.
- iStent Inject – It’s a Micro-Invasive Glaucoma Surgery (MIGS) device and is the second generation of the iStent which was approved in 2012.
- Refresh Repair – An over-the-counter drop that contains osmoprotectants and is focused around the hyperosmotic surface found in dry eye.
- Alleye – A mobile app indicated for the screening and monitoring of macular degeneration.
- Cequa – A prescription eye drop indicated to increase tear production in patients with dry eye. It’s cyclosporin 0.09%.
- Inveltys – It’s loteprednol etabonate ophthalmic suspension 1% and is approved for the treatment of postoperative inflammation and pain following ocular surgery.
- Oxervate – It contains cenegermin which is a recombinant form of human nerve growth factor. It’s approved for the treatment of neurotrophic keratitis.
- Xelpros – It’s latanoprost 0.005%. Xelpros is the only form of latanoprost that is not formulated with benzalkonium chloride (BAK).
- Yutiq – It’s a fluocinolone acetonide intravitreal implant approved for patients with chronic noninfectious posterior uveitis.
- Dextenza – It’s a dexamethasone insert, placed through the punctum into the canaliculus and delivers dexamethasone to the ocular surface for up to 30 days.